食管鳞状细胞癌诊断及治疗最新进展
Recent Progress in Diagnosis and Treatment of Esophageal Squamous Cell Cancel
DOI: 10.12677/acm.2024.14113033, PDF,   
作者: 蒋一胜*, 沈宇杰, 沈 枭：绍兴文理学院医学院，浙江 绍兴；张 楚#：绍兴市人民医院胸外科，浙江 绍兴
关键词: 食管鳞状细胞癌；诊断；治疗；Esophageal Squamous Cell Cancel； Diagnosis； Treatment
摘要: 食管鳞状细胞癌(esophageal squamous cell cancel, ESCC)是一种进行性发展且预后较差的恶性肿瘤，是我国最常见的食管癌类型。食管鳞状细胞癌诊断和治疗具有挑战性。通过血清标志物以及X线、CT、PET/CT、EUS、MRI等影像学检查，可明确诊断食管鳞状细胞癌。治疗方法包括内镜治疗、手术治疗、化疗、放疗、免疫治疗及靶向治疗，单一治疗存在缺点，联合治疗将成为未来ESCC治疗的发展方向。本文主要阐释食管鳞状细胞癌的诊断及治疗最新进展。
Abstract: Esophageal squamous-cell carcinoma carcinoma (ESCC) is a progressive malignant tumor with a poor prognosis. It is the most common type of esophageal carcinoma in our country. The diagnosis and treatment of esophageal squamous-cell carcinoma is challenging. The diagnosis of esophageal squamous-cell carcinoma can be made by serum markers and imaging examinations such as X-ray, CT, PET-CT, EUS and MRI. Treatment methods include endoscopic therapy, surgical therapy, chemotherapy, radiotherapy, immunotherapy and targeted therapy. Single therapy has some disadvantages, and combined therapy will be the development direction of ESCC treatment in the future. This article reviews the latest advances in the diagnosis and treatment of esophageal squamous-cell carcinoma.
文章引用：蒋一胜, 沈宇杰, 沈枭, 张楚. 食管鳞状细胞癌诊断及治疗最新进展[J]. 临床医学进展, 2024, 14(11): 1464-1469. https://doi.org/10.12677/acm.2024.14113033

参考文献

[1] Chen, Y., Zhu, S., Liu, T., Zhang, S., Lu, J., Fan, W., et al. (2023) Epithelial Cells Activate Fibroblasts to Promote Esophageal Cancer Development. Cancer Cell, 41, 903-918.e8. [Google Scholar] [CrossRef] [PubMed]
[2] Wen, T., Wang, W. and Chen, X. (2022) Recent Advances in Esophageal Squamous Cell Precancerous Conditions: A Review. Medicine, 101, e32192. [Google Scholar] [CrossRef] [PubMed]
[3] Sheikh, M., Roshandel, G., McCormack, V. and Malekzadeh, R. (2023) Current Status and Future Prospects for Esophageal Cancer. Cancers, 15, Article 765. [Google Scholar] [CrossRef] [PubMed]
[4] Zhu, H., Ma, X., Ye, T., Wang, H., Wang, Z., Liu, Q., et al. (2022) Esophageal Cancer in China: Practice and Research in the New Era. International Journal of Cancer, 152, 1741-1751. [Google Scholar] [CrossRef] [PubMed]
[5] Silva, M.L.S. (2015) Cancer Serum Biomarkers Based on Aberrant Post-Translational Modifications of Glycoproteins: Clinical Value and Discovery Strategies. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1856, 165-177. [Google Scholar] [CrossRef] [PubMed]
[6] Zhong, L., Li, H., Chang, W., Ao, Y., Wen, Z. and Chen, Y. (2023) TP53 Mutations in Esophageal Squamous Cell Carcinoma. Frontiers in Bioscience-Landmark, 28, Article 219. [Google Scholar] [CrossRef] [PubMed]
[7] Sabapathy, K. and Lane, D.P. (2019) Corrigendum to ‘Understanding P53 Functions through P53 Antibodies’. Journal of Molecular Cell Biology, 11, 1105-1105. [Google Scholar] [CrossRef] [PubMed]
[8] Yang, T., Hui, R., Nouws, J., Sauler, M., Zeng, T. and Wu, Q. (2022) Untargeted Metabolomics Analysis of Esophageal Squamous Cell Cancer Progression. Journal of Translational Medicine, 20, Article No. 127. [Google Scholar] [CrossRef] [PubMed]
[9] 马广婷. 细节护理在消化内科护理中的应用探析[J]. 临床检验杂志(电子版), 2019, 8(3): 180-181.
[10] Ma, D., Zhang, Y., Shao, X., Wu, C. and Wu, J. (2022) PET/CT for Predicting Occult Lymph Node Metastasis in Gastric Cancer. Current Oncology, 29, 6523-6539. [Google Scholar] [CrossRef] [PubMed]
[11] Withey, S.J., Goh, V. and Foley, K.G. (2022) State-of-the-Art Imaging in Oesophago-Gastric Cancer. The British Journal of Radiology, 95, Article 20220410. [Google Scholar] [CrossRef] [PubMed]
[12] Finkenzeller, T., Zorger, N., Kühnel, T., Paetzel, C., Schuierer, G., Stroszczynski, C., et al. (2012) Novel Application of T1-Weighted BLADE Sequences with Fat Suppression Compared to TSE in Contrast-Enhanced T1-Weighted Imaging of the Neck: Cutting-Edge Images? Journal of Magnetic Resonance Imaging, 37, 660-668. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, Y., Mukkamalla, S.K.R., Singh, R., Babiker, H.M. and Lyons, S. (2024) Esophageal Cancer. StatPearls Publishing.
[14] Xiang, G., Xu, C., Chai, G., Lyu, B., Li, Z., Wang, B., et al. (2023) Re-Irradiation for Local Primary-Recurrence Esophageal Squamous Cell Carcinoma Treated with IMRT/VMAT. Radiation Oncology, 18, Article No. 114. [Google Scholar] [CrossRef] [PubMed]
[15] Laios, K., Apostolou, K.G., Vavlas, A., Ntousopoulos, A., Chrysikos, D., Troupis, T., et al. (2023) The History of Esophageal Surgery. Acta Chirurgica Belgica, 123, 712-723. [Google Scholar] [CrossRef] [PubMed]
[16] 杨泽波, 张媛媛, 胡旭. 食管鳞癌Mckeown微创与开放手术的疗效分析[J]. 巴楚医学, 2023, 6(3): 100-104.
[17] Lu, Z., Wang, J., Shu, Y., Liu, L., Kong, L., Yang, L., et al. (2022) Sintilimab versus Placebo in Combination with Chemotherapy as First Line Treatment for Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ORIENT-15): Multicentre, Randomized, Double Blind, Phase 3 Trial. British Medical Journal, 377, e068714. [Google Scholar] [CrossRef] [PubMed]
[18] Sun, J.M., Shen, L., Shah, M.A., Enzinger, P., et al. (2021) KEYNOTE-590 Investigators. Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomized, Placebo-Controlled, Phase 3 Study. The Lancet, 398, 759-771. [Google Scholar] [CrossRef] 
[19] Xu, J., Kato, K., Raymond, E., Hubner, R.A., et al. (2023) Tislelizumab plus Chemotherapy versus Placebo plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (RATIONALE-306): A Global, Randomized, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 24, 483-495. [Google Scholar] [CrossRef] 
[20] Weidenbaum, C. and Gibson, M.K. (2022) Approach to Localized Squamous Cell Cancer of the Esophagus. Current Treatment Options in Oncology, 23, 1370-1387. [Google Scholar] [CrossRef] [PubMed]
[21] Harada, K., Rogers, J.E., Iwatsuki, M., Yamashita, K., Baba, H. and Ajani, J.A. (2020) Recent Advances in Treating Oesophageal Cancer. F1000Research, 9, 1189. [Google Scholar] [CrossRef] [PubMed]
[22] An, L., Li, M. and Jia, Q. (2023) Mechanisms of Radiotherapy Resistance and Radiosensitization Strategies for Esophageal Squamous Cell Carcinoma. Molecular Cancer, 22, Article No. 140. [Google Scholar] [CrossRef] [PubMed]
[23] Puhr, H.C., Preusser, M. and Ilhan-Mutlu, A. (2021) Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? Cancers, 13, Article 4632. [Google Scholar] [CrossRef] [PubMed]
[24] Wei, D.D., Fang, J.M., Wang, H.Z., Chen, J., Kong, S., Jiang, Y., et al. (2024) Perioperative Immunotherapy for Esophageal Squamous Cell Carcinoma. Frontiers in Immunology, 15, Article 1330785. [Google Scholar] [CrossRef] [PubMed]
[25] Huang, Z., Ma, X., Zhang, J., Li, X., Lai, N. and Zhang, S. (2018) Cetuximab for Esophageal Cancer: An Updated Meta-Analysis of Randomized Controlled Trials. BMC Cancer, 18, Article No. 1170. [Google Scholar] [CrossRef] [PubMed]
[26] Yang, Y., Hong, P., Xu, W.W., He, Q. and Li, B. (2020) Advances in Targeted Therapy for Esophageal Cancer. Signal Transduction and Targeted Therapy, 5, Article No. 229. [Google Scholar] [CrossRef] [PubMed]

为你推荐